Anti_Human, mab CD257 Source Mouse
- Known as:
- Anti_Human, mab CD257 Source Mouse
- Catalog number:
- 101-M299
- Product Quantity:
- 100 µg
- Category:
- -
- Supplier:
- Reliatech
- Gene target:
- Anti_Human mab CD257 Source Mouse
Related genes to: Anti_Human, mab CD257 Source Mouse
- Gene:
- TNFSF13B NIH gene
- Name:
- TNF superfamily member 13b
- Previous symbol:
- TNFSF20
- Synonyms:
- BAFF, THANK, BLYS, TALL-1, TALL1, CD257
- Chromosome:
- 13q33.3
- Locus Type:
- gene with protein product
- Date approved:
- 1999-07-19
- Date modifiied:
- 2018-11-22
Related products to: Anti_Human, mab CD257 Source Mouse
Related articles to: Anti_Human, mab CD257 Source Mouse
- Prostate cancer (PCa) is prototypically immunologically "cold", characterized by low tumor mutational burden, sparse CD8 T-cell infiltration, and resistance to immune checkpoint blockade. The tumor cell-intrinsic programs driving immune evasion in this context remain incompletely defined. - Source: PubMed
Publication date: 2026/03/18
Liu WeihaoLi GuopingLei YanLiu HuixiuWang BinhuiDeng WeimingHong YudeLong Xiangyang - Chronic thromboembolic pulmonary hypertension (CTEPH) is driven by unresolved pulmonary arterial thrombi and involves complex processes such as vascular remodeling and immune dysregulation. Early identification of molecular markers may support more accurate diagnosis and individualized therapy. - Source: PubMed
Publication date: 2026/03/31
Liu XiaopengZheng XiaZhang YajunFang YinghuiZhen Yanan - Psoriasis is an immune-mediated chronic skin disease. Despite the low proportion of B cells in human blood, they play an important role in regulating the pathogenesis of psoriasis. Therefore, we investigated the role and clinical significance of B cells in psoriasis by conducting experiments. - Source: PubMed
Wu BohengQin RuLai LichuanLi ShangyangLin RuilanZhang YunlongGuan YaoYuan Yulin - B-cell maturation antigen is highly expressed in myeloma cells and is an attractive target for multiple myeloma (MM) therapies. The extracellular domain of this protein is commonly shed from the plasma cell surface, releasing the soluble antigen that has been proposed as a potential therapeutic biomarker to assess disease burden and activity. Elevated levels of soluble BCMA can lead to target mediated drug disposition (TMDD), thereby interfering with anti-BCMA MM biotherapeutics. Additionally, the presence of natural and therapeutic ligands can increase the complexity and feasibility of biomarker assays used to monitor this soluble antigen. The LC-MS/MS method described here utilizes urea to disrupt ligand binding interactions followed by organic solvent protein precipitation to remove high molecular weight proteins, thereby enriching soluble BCMA from serum while eliminating interference from natural and therapeutic ligands. This assay has sufficient sensitivity to quantify total soluble BCMA in on-treatment samples with an analytical range of 3-1000 ng/mL from 100 μL of serum. The mean recovery across all QC levels in the presence of the natural ligands, APRIL and BAFF, as well as a therapeutic monoclonal antibody, was 101% ± 6.1%. Accuracy of this method across QC levels ranged from 91% to 110.4%. This method has been validated in a GLP compliant manner and the total sBCMA data generated using this assay was used to develop models to inform dosing in a clinical study for a novel monoclonal antibody being investigated to treat relapsed or refractory multiple myeloma. - Source: PubMed
Publication date: 2026/03/19
Henderson Clark MMartin ArlanOrtiz DavidLee Anthony JHengel Shawna M - Lactoferrin (LF) is present in tears, nasal secretions, saliva, and milk and maintains mucosal homeostasis. The palatine tonsils represent the first immune tissue to recognize pathogens invading the oral cavity via Toll-like receptors (TLRs). We aimed to investigate the effects of bovine LF on tonsillar immune cells stimulated with ligands of TLR7 or TLR9, which recognize viral single-stranded RNA or bacterial unmethylated CpG DNA. Mononuclear cells isolated from palatine tonsils of patients with recurrent tonsillitis or immunoglobulin A (IgA) nephropathy were cultured with LF, TLR7, or TLR9 ligands. Under TLR7 stimulation, LF enhanced the activation of plasmacytoid dendritic cells (pDCs), T-killer cells, and B cells without inducing inflammatory cytokines. In contrast, under TLR9 stimulation, LF suppressed the activation of pDCs, myeloid dendritic cells, T-helper cells, T-killer cells, B cells, and natural killer cells, as well as the production of TNF-α and IL-6. Moreover, LF decreased the production of the B-cell activation factor (BAFF), a proliferation-inducing ligand (APRIL), and galactose-deficient IgA1, all of which are risk factors of IgA nephropathy. Overall, LF may enhance the immune response against viruses and contribute to immune tolerance against commensal bacteria in the palatine tonsils, indicating potential benefits in managing cold-like symptoms, recurrent tonsillitis, and IgA nephropathy. - Source: PubMed
Publication date: 2026/03/06
Yago TakumiKujirai ChisaneOda HirotsuguInoue TakahiroOminato HisatakaWakisaka RisaSato RyosukeKono MichihisaYamaki HidekiyoOhara KenzoKumai TakumiTanaka MiyukiTakahara Miki